Skip to content
TrialScanner

NCT05363293

Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects

Phase 1/Phase 2CompletedALZNLead

Registry record

Lead sponsor
Alzamend Neuro, Inc.
Conditions
Alzheimer's Disease; Healthy Non-elderly and Elderly Adults
Primary completion
Apr 14, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05363293 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05363293: Multiple Ascending Dose... | TrialScanner